Monday, November 3, 2025
12:00PM – 1:00PM ET
Please note this virtual program is 12:00PM Eastern, 11:00AM Central, 10:00AM Mountain and 9:00AM Pacific.
FACULTY
 |
Erica L. Mayer, MD, MPH Director, Breast Cancer Clinical Research Breast Oncology Center Dana-Farber Cancer Institute Associate Professor in Medicine Harvard Medical School Boston, Massachusetts |
PROGRAM OVERVIEW
This virtually live continuing education activity is designed to explore the potential of novel, oral endocrine therapies (ET) as first-line therapy for ET-sensitive, hormone-receptor-positive (HR+), HER2-negative metastatic breast cancer. A renowned breast cancer expert will guide you through the latest relevant clinical trial efficacy and safety data in the context of current standards of care. This interactive, case-based program will include a review and discussion of novel ETs, implications of frontline use of oral selective estrogen receptor degraders in overall treatment planning, use of molecular testing to guide biomarker-informed decision making, and best practices in adverse event mitigation, including patient counseling, prevention, monitoring, recognition, and multidisciplinary team care.
TARGET AUDIENCE
This educational activity is intended to meet the educational needs of community oncologists and advanced practice providers who manage patients with advanced breast cancer.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Explain the limitations of standard-of-care endocrine therapies and therapeutic advantages of novel SERDs in the treatment of HR+/HER2- metastatic breast cancer
- Incorporate the latest clinical trial evidence on emerging oral SERDs into treatment planning to optimize treatment decisions for patients with HR+/HER2- metastatic breast cancer
- Interpret molecular testing results to guide biomarker-informed treatment decisions for patients with HR+/HER2- metastatic breast cancer
- Apply knowledge of the toxicity profiles of novel SERDs in HR+/HER2- metastatic breast cancer to recognize, anticipate, and mitigate adverse events, including making appropriate referrals to specialists (eg, cardiology, ophthalmology)
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
